FDG-PET/CT response evaluation during EGFR-TKI treatment in patients with NSCLC

被引：34
作者：
van Gool, Matthijs H. [1 ]
Aukema, Tjeerd S. [2 ]
Hartemink, Koen J. [1 ]
Olmos, Renato A. Valdes [2 ]
van Tinteren, Harm [3 ]
Klomp, Houke M. [1 ]
机构：
[1] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Surg Oncol, Plesmanlaan 121, NL-1066 CX Amsterdam, Netherlands
[2] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Nucl Med, NL-1066 CX Amsterdam, Netherlands
[3] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Dept Biometr, NL-1066 CX Amsterdam, Netherlands
来源：
WORLD JOURNAL OF RADIOLOGY | 2014年 / 6卷 / 07期
关键词：
Non-small cell lung cancer; Epidermal growth factor receptor-tyrosine kinase inhibitors therapy; Positron emission tomography-computed tomography; Computed tomography; Response monitoring;
D O I：
10.4329/wjr.v6.i7.392
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
Over recent years, [18F]-fluorodeoxyglucose positron emission tomography acquired together with low dose computed tomography (FDG-PET/CT) has proven its role as a staging modality in patients with non-small cell lung cancer (NSCLC). The purpose of this review was to present the evidence to use FDG-PET/CT for response evaluation in patients with NSCLC, treated with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI). All published articles from 1 November 2003 to 1 November 2013 reporting on 18FFDG-PET response evaluation during EGFR-TKI treatment in patients with NSCLC were collected. In total 7 studies, including data of 210 patients were eligible for analyses. Our report shows that FDG-PET/CT response during EGFR-TKI therapy has potential in targeted treatment for NSCLC. FDG-PET/CT response is associated with clinical and radiologic response and with survival. Furthermore FDG-PET/CT response monitoring can be performed as early as 1-2 wk after initiation of EGFR-TKI treatment. Patients with substantial decrease of metabolic activity during EGFR-TKI treatment will probably benefit from continued treatment. If metabolic response does not occur within the first weeks of EGFR-TKI treatment, patients may be spared (further) unnecessary toxicity of ineffective treatment. Refining FDG-PET response criteria may help the clinician to decide on continuation or discontinuation of targeted treatment. (c) 2014 Baishideng Publishing Group Inc. All rights reserved.
引用
收藏
页码：392 / 398
页数：7
相关论文
共 33 条
[1]   Non-small cell lung cancer: Dual-modality PET/CT in preoperative staging [J].
Antoch, G ;
Stattaus, J ;
Nemat, AT ;
Marnitz, S ;
Beyer, T ;
Kuehl, H ;
Bockisch, A ;
Debatin, JF ;
Freudenberg, LS .
RADIOLOGY, 2003, 229 (02) :526-533
[2]   Is 18F-FDG PET/CT Useful for the Early Prediction of Histopathologic Response to Neoadjuvant Erlotinib in Patients with Non-Small Cell Lung Cancer? [J].
Aukema, Tjeerd S. ;
Kappers, Ingrid ;
Olmos, Renato A. Valdes ;
Codrington, Henk E. ;
van Tinteren, Harm ;
van Pel, Renee ;
Klomp, Houke M. .
JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (09) :1344-1348
[3]  
Benz MR, 2011, J NUCL MED, V52, P1684, DOI 10.2967/jnumed.111.095257
[4]   Targeted therapies in lung cancer [J].
Besse, B. ;
Ropert, S. ;
Soria, J. C. .
ANNALS OF ONCOLOGY, 2007, 18 :135-142
[5]   Chemotherapy response evaluation with FDG-PET in patients with colorectal cancer [J].
de Geus-Oei, L. F. ;
van Laarhoven, H. W. M. ;
Visser, E. P. ;
Hermsen, R. ;
van Hoorn, B. A. ;
Kamm, Y. J. L. ;
Krabbe, P. F. M. ;
Corstens, F. H. M. ;
Punt, C. J. A. ;
Oyen, W. J. G. .
ANNALS OF ONCOLOGY, 2008, 19 (02) :348-352
[6]   Lung cancer histologic type in the surveillance, epidemiology, and end results registry versus independent review [J].
Field, RW ;
Smith, BJ ;
Platz, CE ;
Robinson, RA ;
Neuberger, JS ;
Brus, CP ;
Lynch, CF .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (14) :1105-1107
[7]   Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: Implications for clinical practice and open issues [J].
Gridelli, C. ;
De Marinis, F. ;
Di Maio, M. ;
Cortinovis, D. ;
Cappuzzo, F. ;
Mok, T. .
LUNG CANCER, 2011, 72 (01) :3-8
[8]   Prognostic relevance of response evaluation using [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer [J].
Hoekstra, CJ ;
Stroobants, SG ;
Smit, EF ;
Vansteenkiste, J ;
van Tinteren, H ;
Postmus, PE ;
Golding, RP ;
Biesma, B ;
Schramel, FJHM ;
van Zandwijk, N ;
Lammertsma, AA ;
Hoekstra, OS .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (33) :8362-8370
[9]   Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen [J].
Johnson, JR ;
Cohen, M ;
Sridhara, R ;
Chen, YF ;
Williams, GM ;
Duan, J ;
Gobburu, J ;
Booth, B ;
Benson, K ;
Leighton, J ;
Hsieh, LS ;
Chidambaram, N ;
Zimmerman, P ;
Pazdur, R .
CLINICAL CANCER RESEARCH, 2005, 11 (18) :6414-6421
[10]   Molecular Diagnosis of Activating EGFR Mutations in Non-Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis [J].
Kawahara, Akihiko ;
Yamamoto, Chizuko ;
Nakashima, Kazutaka ;
Azuma, Koichi ;
Hattori, Satoshi ;
Kashihara, Masaki ;
Aizawa, Hisamichi ;
Basaki, Yuji ;
Kuwano, Michihiko ;
Kage, Masayoshi ;
Mitsudomi, Tetsuya ;
Ono, Mayumi .
CLINICAL CANCER RESEARCH, 2010, 16 (12) :3163-3170
1234